Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Envisagenics

Envisagenics

Envisagenics is a biotechnology company founded by Maria Luisa Pineda and Martin Akerman in 2014 and headquartered in New York City, New York using artificial intelligence and RNA sequencing to develop therapeutics to treat genetic diseases.

Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.

Envisagenics looks to provide means to reduce biomedical data in order to accelerate the creation of new therapeutic solutions. They are focused on finding solutions that help accommodate people who are affected by genetic diseases or cancer, especially if caused by mutations that affect RNA splicing.

Their technologies are designed to accelerate target identification for RNA splicing error discovery, as well as RNA therapeutic design and validation which they perform on their dedicated artificial intelligence discovery platform, and to increase the value of RNA sequencing data.

Funding
Seed round

On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.

Timeline

September 2021
Envisagenics raises a $19,200,000 series A round from Red Cell Partners.
May 2018
Envisagenics raises a $1,500,000 grant from National Institutes of Health.
May 2018
Envisagenics raises a $1,000,000 seed round from M12 and Madrona Venture Group.
November 2017
Envisagenics raises a $2,400,000 seed round from Cosine, Dolby Family Ventures, Dynamk Capital, New York State, SV Angel and Third Kind Venture Capital.
April 2017
Envisagenics raises a $350,000 grant from The Thiel Foundation.
August 2015
Envisagenics raises a $225,000 grant from National Institutes of Health.
April 22, 2014
Envisagenics was founded by Maria Luisa Pineda and Martin Akerman.

Funding rounds

SBIR/STTR Awards

Patents

Further reading

Title
Author
Link
Type
Date

Envisagenics (@envisagenics) | Twitter

Envisagenics

Web

December 10, 2013

Microsoft Announces Winners of AI Startup Competition

Meir Orbach

Web

Platform Targeting Genetic Cause of SMA and Like Diseases Supported by $1.5M NIH Grant

Carolina Henriques

Web

Documentaries, videos and podcasts

Title
Date
Link

News

Title
Author
Date
Publisher
Description
FinSMEs
October 1, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

References

Golden logo
By using this site, you agree to our Terms & Conditions.